Share this post: Share on X (Twitter) Share on Facebook Share on LinkedIn Share on EmailThe results from the recent GLAGOV trial suggest that aggressive lowering of LDL-cholesterol with a PCSK9-inhibitor on top of statin therapy in patients with coronary artery disease may reduce atherosclerotic plaque burden. Although these results provide support for the lipid … Continue reading GLAGOV – The Lipid Hypothesis Gains Ground